The global renal biomarkers market is anticipated to grow at a considerable CAGR of 8.7% during the forecast period (2022-2028). The renal biomarkers, diagnose the patients at risk of developing kidney diseases, by measuring their blood or urine levels. They are generally released in acute or chronic kidney injuries, which are considered by the prompt or measured loss of kidney function causing serious clinical consequences. The early identification of kidney diseases benefits to take timely preventive steps before the damage becomes irreversible. The major factors contributing to the growth of the global renal biomarker market include advances in the biomarker intended, for improving lives of the patients with kidney diseases. Also, the Increasing prevalence of chronic disease boosts the market growth. The Rising number of people with high blood pressure coupled with the generic population, increasing awareness of kidney-related diseases contributing to considerable growth in the market. However, The Absence of monitoring and reimbursement systems and limited market capabilities in the under-developed markets restrain the growth of the market. To gain the opportunity key players operating in the global Renal Biomarker market are adopting R&D, and FDA approval strategies to gain major market share in the global market.
Browse the full report description of “Global Renal Biomarker Market Research, By Type (Diagnostic Biomarkers, Prognostic Biomarkers, Predictive Biomarkers, Pharmacodynamic Biomarkers), By Diagnostic technique (Elisa, Colorimetric Assay, Liquid Chromatography-Mass Spectrometry, Particle-Enhanced Turbidimetric Immunoassay), By End-User Industry (Hospitals, Diagnostic Labs, Research Centres), and Forecast 2022-2028” at https://www.omrglobal.com/industry-reports/renal-biomarker-market
For instance, in February 2021, bioMerieux announced the CE pattern of the advanced NEPHROCHECK examination to identify kidney stress in patients at risk of acute kidney injury (AKI). NEPHROCHECK is an advanced test that diagnoses kidney stress before actual damage when a timely intervention can still make a difference. AKI is a common problem, distressing between 7 and 18% of all hospitalized patients. Delays in diagnosing AKI can lead to permanent consequences.
Market Coverage
• The market number available for 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
o By Type
o By Diagnostic Technique
o By End-User
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
Competitive Landscape – Abbott Laboratories, Bayer AG, Novartis AG, Pacific Biomarkers, Siemens AG, and others.
Key questions addressed by the report
• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?
Global Renal Biomarker Market
By Type
By Diagnostic Technique
By End-User
Global Renal Biomarker Market by Region
North America
• US
• Canada
Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
Rest of the World
• Latin America
• Middle East & Africa
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/renal-biomarker-market